Probi AB is a Swedish biotechnology company specializing in the development, production, and delivery of clinically proven probiotic and biotic solutions. Founded in 1991 at Lund University, it originated from research demonstrating the health benefits of specific probiotic strains, such as Lactiplantibacillus plantarum 299v (LP299V®), its most studied strain.
Headquartered in Lund with manufacturing facilities in the US (Redmond and Lafayette) and sales offices worldwide, Probi operates in over 40 markets. It holds more than 350 global patents and focuses on applications including digestive health, immune support, metabolic health, bone health, iron absorption, women's health, mental health, and healthy aging. Products are supplied in bulk, supplements, and functional foods to B2B partners.
Acquired by Symrise AG and fully owned by January 2025, Probi now integrates into Symrise's Care & Wellness Division within the Scent & Care segment, enhancing offerings in health actives, biotics, and holistic wellness solutions.
None yet. When a new project in the record names Probi as owner, partner or investor, it shows here.
New studies: Acerowell improved skin radiance at 600 mg/day; Rham271h postbiotic at 10B TFU supports immune and gut‑barrier markers; LP299V+LPGOS42 improved constipation and regularity.
The new division integrates cosmetic ingredients, health actives, and biotics to meet demand for holistic care solutions, enhancing innovation and market readiness.
